Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine in Myelodysplastic Syndromes
NCT00003361Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 1998
- Primary completion
- Sep 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of decitabine in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Response Rate. Started Apr 1998; status: completed.
02
Drugs
decitabine
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT00003361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003361.